Acne vulgaris is the most common disease involving the pilosebaceous unit. It is rarely misdiagnosed. It occurs at the site where there are sebaceous follicles and thus occurs predominantly on the face, back and chest. It occurs in all races and affects both sexes. The onset of acne is usually in early adolescence and affects up to 80% of all individuals. The milder physiological acne which affects many adolescents will last for 4 or 5 years, but the more clinical varieties will last for 12, and sometimes even 40 or 50 years.


Benzoyl Peroxide Topical Therapy Azelaic Acid Hidradenitis Suppurativa Clobetasol Propionate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Cunliffe WJ, Clayden AD, Gould D et al. (1981) Acne vulgaris - its aetiology and treatment. A review. Clin Exp Dermatol 6: 461–469CrossRefGoogle Scholar
  2. 2.
    Katsambas A. (1998) Why and when the treatment of acne fails. What to do Dermatology 196: 158–161CrossRefGoogle Scholar
  3. 3.
    Lyons RE (1978) Comparative effectiveness of benzoyl peroxide and tretinoin in acne vulgaris. Int J Dermatol 17: 246–251PubMedCrossRefGoogle Scholar
  4. 4.
    Chalker DK, Lesher JL, Smith JG et al. (1987) Efficacy of topical isotretinoin 0.05% gel in acne vulgaris: Results of a multicenter, double-blind investigation. J Am Acad Dermatol 17: 251–254PubMedCrossRefGoogle Scholar
  5. 5.
    Shalita A, Weiss JS, Chalker DK, Elis CN, Greenspa A, Katz HI, Kantor I, Millikan LE, Swinhart T, Swinyer L, Whitmore C, Baker M, Czernielewski J (1996) A comparison of the efficacy and safety of adapalene gel 0.1% and tretinoin gel 0.025% in the treatment of acne vulgaris: a multicenter trial. J Am Acad Dermatol 34: 482–485PubMedCrossRefGoogle Scholar
  6. 6.
    Eady EA, Jones CE, Tipper JL, Cove JH, Cunliffe WJ, Layton AM (1993) Antibiotic resistant propionibacteria in acne: need for policies to modify antibiotic usage. BMJ 306: 555–556PubMedCrossRefGoogle Scholar
  7. 7.
    Schaefer H (1993) Penetration and percutaneous absorption of topical retinoids. A review. Skin Pharmacol 6: 17–23PubMedCrossRefGoogle Scholar
  8. 8.
    Bottomley WW, Cunliffe W (1993) Oral trimethoprim as a third-line antibiotic in the management of acne vulgaris. Dermatol 187: 193–196CrossRefGoogle Scholar
  9. 9.
    Goulden V, Glass D, Cunliffe WJ (1996) Safety of long term high dose minocycline in the treatment of acne. Brit J Dermatol 134: 693–695CrossRefGoogle Scholar
  10. 10.
    Seukeran DC, Eady AE, Cunliffe WJ (1997) Benefit-risk assessment of acne therapies. Lancet 349: 1251PubMedCrossRefGoogle Scholar
  11. 11.
    Hammerstein J, Cupceancu B (1969) Behandlung des Hirsutismus mit Cyproteronacetat. Dtsch Med Wochenschr 94: 829–834PubMedCrossRefGoogle Scholar
  12. 12.
    Strauss JS, Rapini RP, Shalita AR et al. (1984) Isotretinoin therapy for acne: results of a multicenter dose-response study. J Am Acad Dermatol 10: 490–496PubMedCrossRefGoogle Scholar
  13. 13.
    Goulden V, Layton AM, Cunliffe WJ (1995) Current indications for isotretinoin as a treatment for acne vulgaris. Dermatology 190: 284–287PubMedCrossRefGoogle Scholar
  14. 14.
    Cunliffe WJ, Van der Kerkhof PCM, Caputo R et al. (1994) Roaccutane treatment guidelines, results of an international survey. Dermatology: 351–357Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2000

Authors and Affiliations

  • W. J. Cunliffe
  • D. C. Seukeran

There are no affiliations available

Personalised recommendations